- Home
- LPTX vs SABS Comparison
LPTX vs SABS Comparison
Compare LPTX & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- SABS
- Stock Information
- Founded
- LPTX 2011
- SABS 2014
- Country
- LPTX United States
- SABS United States
- Employees
- LPTX N/A
- SABS N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- LPTX Health Care
- SABS Health Care
- Exchange
- LPTX Nasdaq
- SABS Nasdaq
- Market Cap
- LPTX 35.4M
- SABS 31.2M
- IPO Year
- LPTX N/A
- SABS N/A
- Fundamental
- Price
- LPTX $0.48
- SABS $3.04
- Analyst Decision
- LPTX Hold
- SABS Strong Buy
- Analyst Count
- LPTX 1
- SABS 3
- Target Price
- LPTX N/A
- SABS $9.00
- AVG Volume (30 Days)
- LPTX 7.7M
- SABS 452.5K
- Earning Date
- LPTX 11-13-2025
- SABS 11-06-2025
- Dividend Yield
- LPTX N/A
- SABS N/A
- EPS Growth
- LPTX N/A
- SABS N/A
- EPS
- LPTX N/A
- SABS N/A
- Revenue
- LPTX N/A
- SABS $114,698.00
- Revenue This Year
- LPTX N/A
- SABS N/A
- Revenue Next Year
- LPTX N/A
- SABS N/A
- P/E Ratio
- LPTX N/A
- SABS N/A
- Revenue Growth
- LPTX N/A
- SABS N/A
- 52 Week Low
- LPTX $0.22
- SABS $1.00
- 52 Week High
- LPTX $4.79
- SABS $6.60
- Technical
- Relative Strength Index (RSI)
- LPTX 47.84
- SABS 65.96
- Support Level
- LPTX $0.43
- SABS $2.90
- Resistance Level
- LPTX $0.56
- SABS $3.19
- Average True Range (ATR)
- LPTX 0.06
- SABS 0.23
- MACD
- LPTX -0.02
- SABS 0.06
- Stochastic Oscillator
- LPTX 16.04
- SABS 86.24
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.